Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Siegmund, B; Högenauer, C; Novacek, G; Petritsch, W; Reinisch, W; Schoepfer, A; Schreiber, S; Vavricka, S; Bokemeyer, B, , für, die, IBD-Dach-Gruppe.
[Ustekinumab - Current position].
Z Gastroenterol. 2018; 56(9):1077-1086
Doi: 10.1055/a-0655-2425
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Hoegenauer Christoph
- Petritsch Wolfgang
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The present review by the IBD-Dach group provides a comprehensive summary of the mode of action, clinical development, approval, efficacy and safety aspects of the novel anti-p40 antibody Ustekinumab. The review provides current data, including the large clinical trials as well as smaller case series and work outside the field of inflammatory bowel diseases for shedding more light into special situations. Together, the data indicate that Ustekinumab shows clinical efficacy as well as a good safety profile for the treatment of Crohn's disease.
- Find related publications in this database (using NLM MeSH Indexing)
- Crohn Disease - drug therapy
- Humans - administration & dosage
- Inflammatory Bowel Diseases - drug therapy
- Treatment Outcome - administration & dosage
- Ustekinumab - adverse effects, pharmacology, therapeutic use
- Find related publications in this database (Keywords)
- inflammatory bowel disease
- Crohn's disease
- biologicals
- ustekinumab